Nadeem Kazi, MD
Gastroenterology · Casa Grande, AZNPI 1518963198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 71.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $209 and has fallen 73.4% since, to $56 in 2024. That places this record below the midpoint for gastroenterology clinicians in AZ, where the typical reported total is $3,568.
Across 37 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$416
- Intuitive Surgical$73
- Takeda Pharmaceuticals U.S.A., Inc.$58
- Ferring Pharmaceuticals Inc.$22
- Pfizer$13
What the payments were for
- Food & beverage$56898%
- Education$132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 32 | $416 |
| Intuitive Surgical | 1 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $13 |
How this compares
$581 in reported general payments places this provider in the 20th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HumiraAdalimumab | 12 | $85,564 |
| LinzessLinaclotide | 80 | $59,266 |
| XifaxanRifaximin | 16 | $57,449 |
| Mesalamine | 41 | $17,859 |
| Pantoprazole Sodium | 777 | $8,390 |
| Ursodiol | 35 | $6,829 |
| Omeprazole | 492 | $6,818 |
| Famotidine | 333 | $6,714 |
| CreonLipase/Protease/Amylase | 12 | $6,478 |
| Mesalamine ErMesalamine | 14 | $2,511 |
| Budesonide DrBudesonide | 20 | $2,423 |
| Lactulose | 34 | $1,845 |
| Lubiprostone | 14 | $1,461 |
| Sucralfate | 25 | $704 |
| Clarithromycin | 16 | $649 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Casa Grande
- Joel BrillParadise Valley$847K
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Neil SharmaGilbert$405K
- Chirag TrivediSun City$400K
- David LeffMesa$377K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.